Gujarat Themis Biosyn Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Gujarat Themis Biosyn Ltd filed with BSE on 14 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Gujarat Themis Biosyn reported Q1 FY27 revenue of INR43.8 crores, up 22.1% year-on-year, with EBITDA growing 49.4% to INR20.8 crores at a 47.5% margin. Management discussed two announced acquisitions, MicroBiopharm Japan and a portfolio of 13 brands from Sanofi France, describing plans to fund them through a mix of equity and debt. Management also addressed expanded fermentation capacity, the API block ramp-up, and a resolved dispute with Optimus Drugs.
Numbers mentioned
Revenue from operations: INR43.8 crores (Q1 FY27)
p. 5
“Revenue from operations for Q1 FY27 stood at INR43.8 crores compared with INR35.9 crores in the corresponding quarter last year, an increase of 22.1% year-on-year.”
Krupesh Patel, page 5 of the filed PDF · View the filing
EBITDA: INR20.8 crores (Q1 FY27)
p. 5
“EBITDA for the quarter grew by 49.4% year-on-year to INR20.8 crores with an EBITDA margin of 47.5%, up by 867 basis points.”
Krupesh Patel, page 5 of the filed PDF · View the filing
Profit after tax: INR11.1 crores (Q1 FY27)
p. 5
“Profit after tax stood at INR11.1 crores compared with INR9.1 crores in Q1 FY26, reflecting a growth of 22.1% year-on-year.”
Krupesh Patel, page 5 of the filed PDF · View the filing
Gross block: INR435 crores (FY26)
p. 12
“if you see the FY26 balance sheet, it is around INR435 crores, including CWIP.”
Krupesh Patel, page 12 of the filed PDF · View the filing
Gross block: INR62 crores (FY23)
p. 12
“So if you see on gross block side, so our gross block was around INR62 crores in FY23.”
Krupesh Patel, page 12 of the filed PDF · View the filing
Incremental gross block addition: INR370 crores (FY23-FY26)
p. 12
“So if you see, we have incrementally added around INR370 crores in last 3 years in gross block.”
Krupesh Patel, page 12 of the filed PDF · View the filing
MicroBiopharm revenue split by geography: 60% Japan, 40% outside Japan
p. 15
“60% is in Japan, 40% is outside Japan.”
Sachin Patel, page 15 of the filed PDF · View the filing
MicroBiopharm CDMO share of business: 60%
p. 15
“And 60% of their business is currently CDMO.”
Sachin Patel, page 15 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Equity raise — up to INR1,000 crores
stated firmly by Sachin Patel
p. 10
“Right now, I think what we have decided is that we are raising equity up to INR1,000 crores.”
Sachin Patel, page 10 of the filed PDF · View the filing
Base business capex — about INR20 crores · FY27
stated firmly by Sachin Patel
p. 11
“So most of our capex is now completed. I think probably to do some last do the last mile thing, we may have a little bit left, about INR10 crores to INR15 crores, but otherwise, most of the capex is already done by the company.”
Sachin Patel, page 11 of the filed PDF · View the filing
Revenue growth — high-teen basis · next 3 to 5 years
stated as an aspiration by Krupesh Patel
p. 12
“I can say we are -- on a base case basis, we want to grow on high-teen basis, I can say.”
Krupesh Patel, page 12 of the filed PDF · View the filing
Expanded fermentation capacity utilization — full scale operation · by end of this month
stated firmly by Sachin Patel
p. 8
“So the expanded capacity will be fully operational and running and producing by the end of this month.”
Sachin Patel, page 8 of the filed PDF · View the filing
Output from expanded capacity — this quarter and second half of the year
stated firmly by Sachin Patel
p. 9
“We should start seeing the output from the expanded capacity to a certain extent from this quarter and then finally in the second half of the year.”
Sachin Patel, page 9 of the filed PDF · View the filing
Hybrid power plant Phase 1 — go live · September
stated firmly by Sachin Patel
p. 17
“We are expecting Phase 1 to go live in September.”
Sachin Patel, page 17 of the filed PDF · View the filing
Sanofi manufacturing transfer completion — complete manufacturing control · within 3 years, tech transfers in first year
stated conditionally by Sachin Patel
p. 10
“We hope much earlier. We hope much earlier. But yes, 3 years is the maximum time that would take. So all the tech transfers, etcetera, would be complete in the first year itself.”
Sachin Patel, page 10 of the filed PDF · View the filing
Promoter pledge reduction — within a year to 15 months
stated as an aspiration by Sachin Patel
p. 11
“I think within a year, it should be going down year to 15 months should be going down significantly.”
Sachin Patel, page 11 of the filed PDF · View the filing
MBJ synergy projects — within the first year
stated conditionally by Sachin Patel
p. 19
“We expect some projects to start within the first year.”
Sachin Patel, page 19 of the filed PDF · View the filing
Margin post-integration of Sanofi and MBJ — close to current margins
stated as an aspiration by Sachin Patel
p. 16
“We would hope that once this integration is completed and once the stabilization is done, we would be -- we'll be close to where we are right now.”
Sachin Patel, page 16 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said interest costs in the target geographies are lower than assumed and the acquired business is cash flow positive from the start.
Answered by Sachin Patel
Asked by Harsh Upadhyay: How does the acquisition financing make sense given expected interest burden versus initial revenue contribution?
p. 6
“the interest cost is significantly lower than the 10% that you have mentioned. So we don't see interest outflow to the tune of the number that you mentioned. And the way we see it from the very beginning, this business is actually cash flow positive.”
Sachin Patel, page 6 of the filed PDF · View the filing
Management said fermentation capacity constraints delayed the API block until existing customer supply commitments could be maintained.
Answered by Sachin Patel
Asked by Harsh Upadhyay: Why did API block revenues not show up despite earlier guidance for FY25?
p. 6
“So essentially, our API block, although we were planning to start it immediately, it took a lot of time because we did not have enough capacity in the fermentation blocks.”
Sachin Patel, page 6 of the filed PDF · View the filing
Management said all platforms except ADCs are already commercialized with at least one product, while ADCs technology exists but has no bagged project yet.
Answered by Sachin Patel
Asked by Nirali Shah: Which MicroBiopharm platforms are commercialized versus still developing, such as ADCs?
p. 8
“But all the other technologies, meaning peptides, plasmids, onco, precision fermentation, immunosuppressants, anti-infectives, these are all commercialized or at least one product from each of them is commercialized.”
Sachin Patel, page 8 of the filed PDF · View the filing
Management said one funding avenue is closed and multiple approaches are being kept ready to determine the optimal debt-equity mix before closing.
Answered by Sachin Patel
Asked by Saloni Arya: Has funding been secured for the MicroBiopharm Japan deal, and what is the purpose of the additional debt facility and guarantee?
p. 9
“So we have -- we are preparing for multiple avenues in terms of funding. So we have one avenue closed, but we would like to work with the optimal mix of debt and equity.”
Sachin Patel, page 9 of the filed PDF · View the filing
Management said a transition service agreement will govern a step-by-step transfer to CMOs over up to three years, with tech transfers completed in the first year.
Answered by Sachin Patel
Asked by Mithun Maity: Who will manufacture the Sanofi portfolio molecules post-closing?
p. 9
“After post-closing, there is a transition service agreement between us and Sanofi for 3 years, whereby in a step-by-step manner, all the transfers will take place.”
Sachin Patel, page 9 of the filed PDF · View the filing
Management said both acquired businesses have been historically steady and the strategy is to add synergies rather than turn around distressed businesses.
Answered by Sachin Patel
Asked by Hitesh: How is management addressing risks of digesting two large overseas acquisitions and leverage exposure?
p. 18
“So both the businesses that we are looking at have been very steady historically. There has been no major upside nor downside in any of the businesses.”
Sachin Patel, page 18 of the filed PDF · View the filing
Management declined to give details citing confidentiality but confirmed the dispute is resolved and business has restarted.
Answered by Sachin Patel
Asked by Harsh Upadhyay: What was behind the dispute with Optimus Drugs and how was it resolved?
p. 17
“So I will -- because of confidentiality reasons, I will not get into the details of it, but the good news is that, that dispute is behind us, and we are restarting business.”
Sachin Patel, page 17 of the filed PDF · View the filing
Risks flagged
Production impacted in a prior year by excessive rains and power fluctuations
p. 13
“So there may have been 1 year which -- where you would have seen a little bit of reduction because of some production-related issues because of excessive rains and power fluctuations.”
Sachin Patel, page 13 of the filed PDF · View the filing
Regulatory approvals required from over 50 countries could delay the second acquisition
p. 6
“The reason for that essentially being that there are significant regulatory approvals that have to be obtained from over 50 countries.”
Sachin Patel, page 6 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.